Physician profile
Beth A Pyle-Smith
NPI 1194728485
$3,350.51
in general payments reported to CMS, 2019-2025
12 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $53.97 · 2021: $1,119 · 2022: $428 · 2023: $221 · 2024: $779 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,252.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,307.85 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $494.73 | 2019-2025 | Precision 7, Dailies Total1 |
| Biotissue Holdings INC. | $467.43 | 2021-2024 | |
| Coopervision INC. | $333.59 | 2019-2025 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $196.57 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $155.79 | 2019 | |
| Sight Sciences, INC. | $149.46 | 2021 | |
| Oyster Point Pharma, INC. | $127.26 | 2024 | Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $47.03 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $34.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.84 | 2021 | |
| Allergan, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Pyle-Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.